Activated Leukocyte Cell Adhesion Molecule Is a Marker for Thyroid Carcinoma Aggressiveness and Disease-Free Survival-Reference-Cited by-同舟云学术

Activated Leukocyte Cell Adhesion Molecule Is a Marker for Thyroid Carcinoma Aggressiveness and Disease-Free Survival

Published:2013-02 Issue:2 Volume:23 Page:201-208
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Chaker Seham¹²,Kak Ipshita¹,MacMillan Christina³,Ralhan Ranju¹³⁴⁵,Walfish Paul G.¹³⁴⁵⁶

Affiliation:

1. Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada.

2. Institute of Medical Science, University of Toronto, Toronto, Canada.

3. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.

4. Department of Otolaryngology–Head and Neck Surgery, Joseph and Mildred Sonshine Family Center for Head and Neck Diseases, Mount Sinai Hospital, Toronto, Canada.

5. Department of Otolaryngology–Head and Neck Surgery, University of Toronto, Toronto, Canada.

6. Endocrine Division, Department of Medicine, Mount Sinai Hospital, Toronto, Canada.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2012.0405

Reference38 articles.

1. Thyroid Cancer Epidemiology and Prognostic Variables

2. Increasing incidence of thyroid cancer: is diagnostic scrutiny the sole explanation?

3. Cancers with increasing incidence trends in the United States: 1999 through 2008

4. Pathology and genetics of thyroid carcinoma

5. Early Recurrence of Papillary and Follicular Thyroid Carcinoma Predicts a Worse Outcome

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurement of CD166 in Egyptian adult patients with acute lymphoblastic leukemia and its relation to clinical outcome;The Egyptian Journal of Haematology;2023-07

2. Expression of ALCAM in Clinical Colon Cancer and Relationship With Patients’ Treatment Responses;In Vivo;2023

3. The Clinical and Theranostic Values of Activated Leukocyte Cell Adhesion Molecule (ALCAM)/CD166 in Human Solid Cancers;Cancers;2021-10-15

4. Recent progress on developing of plasmon biosensing of tumor biomarkers: Efficient method towards early stage recognition of cancer;Biomedicine & Pharmacotherapy;2020-12

5. A systematic evaluation for the potential translation of CD166-related expression as a cancer biomarker;Expert Review of Molecular Diagnostics;2016-07-25